{"id":1068508,"date":"2024-04-09T13:01:08","date_gmt":"2024-04-09T17:01:08","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/rapt-therapeutics-announces-promising-results-from-phase-2-trial-of-tivumecirnon-in-combination-with-anti-pd-1-immunotherapy-in-cpi-experienced-head\/"},"modified":"2024-08-18T11:48:05","modified_gmt":"2024-08-18T15:48:05","slug":"rapt-therapeutics-announces-promising-results-from-phase-2-trial-of-tivumecirnon-in-combination-with-anti-pd-1-immunotherapy-in-cpi-experienced-head","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/rapt-therapeutics-announces-promising-results-from-phase-2-trial-of-tivumecirnon-in-combination-with-anti-pd-1-immunotherapy-in-cpi-experienced-head.php","title":{"rendered":"RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head&#8230;"},"content":{"rendered":"<p><![CDATA[- Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status]]><\/p>\n<p>View original post here:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/04\/09\/2860241\/0\/en\/RAPT-Therapeutics-Announces-Promising-Results-from-Phase-2-Trial-of-Tivumecirnon-in-Combination-with-Anti-PD-1-Immunotherapy-in-CPI-Experienced-Head-and-Neck-Cancer-Patients.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head...\">RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>View original post here: RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head... <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/rapt-therapeutics-announces-promising-results-from-phase-2-trial-of-tivumecirnon-in-combination-with-anti-pd-1-immunotherapy-in-cpi-experienced-head.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068508","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068508"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068508"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068508\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}